Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Ms. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors.– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
– Warner Biddle被任命爲首席執行官並加入董事會，帶來超過30年的商業、產品規劃和特許經營領導經驗，包括在血液學CAR-T先驅成功推出。
– Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors
– Christi Shaw，生命科學領域的領導者，曾任職於多家重要的藥品和生物技術公司，對多個治療領域都有經驗，被任命爲董事會成員。
– Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Development, Manufacturing, Commercial Launch and Expansion
– 共同加強領導力，作爲細胞治療的開拓者，具有領導臨床開發、製造業-半導體、商業推出和拓展的豐富經驗。
EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Ms. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors.
加利福尼亞州埃默裏維爾，2024年9月16日/新華社/ -- Kyverna Therapeutics, Inc.（Kyverna）是一家以患者爲中心、臨床階段的生物藥公司，專注於爲患有自身免疫性疾病的患者開發細胞療法。今天宣佈任命Warner Biddle爲公司的首席執行官（CEO）和董事會成員。Biddle先生接替了Peter Maag博士的CEO職務和董事會成員職務，Peter Maag博士已立即辭去這些職務。此外，Kyverna宣佈任命Christi Shaw爲其董事會成員。Shaw女士接替了Brian Kotzin博士的職位，Brian Kotzin博士已決定從董事會辭職。
譯文內容由第三人軟體翻譯。